Gerresheimer AG (GRRMF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Gerresheimer AG (GRRMF) es una empresa del sector Healthcare valorada en 0. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Gerresheimer AG (GRRMF) Resumen de Asistencia Médica y Tuberías
Gerresheimer AG manufactures specialized packaging solutions and drug delivery systems for the healthcare industry, focusing on plastics, glass, and advanced technologies. With a global presence and a history dating back to 1864, the company serves pharmaceutical, biotech, and cosmetic sectors with a diverse product portfolio.
Tesis de Inversión
Gerresheimer AG presents an investment opportunity within the healthcare sector, driven by its diverse product portfolio and global presence. The company's focus on drug delivery systems and specialized packaging caters to the growing demand for advanced healthcare solutions. With a market capitalization of $0.75 billion and a P/E ratio of 26.14, Gerresheimer exhibits a moderate valuation. Key growth catalysts include the expansion of its Advanced Technologies division and increasing demand for injectable drugs. However, investors may want to evaluate the company's relatively low profit margin of 1.0% and potential risks associated with regulatory changes and competition. The dividend yield is 0.23%.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.75 billion indicates a mid-sized player in the medical instruments and supplies market.
- P/E ratio of 26.14 suggests a moderate valuation compared to its earnings.
- Profit margin of 1.0% reflects a need for improved operational efficiency.
- Gross margin of 26.9% indicates the profitability of its products before operating expenses.
- Dividend yield of 0.23% provides a modest income stream for investors.
Competidores y Pares
Fortalezas
- Global presence and established reputation in the healthcare industry.
- Diverse product portfolio spanning packaging, drug delivery systems, and advanced technologies.
- Long-standing relationships with major pharmaceutical companies.
- Expertise in regulatory compliance and quality control.
Debilidades
- Relatively low profit margin compared to industry peers.
- Dependence on the pharmaceutical industry, making it susceptible to regulatory changes.
- Limited brand recognition among consumers.
- Exposure to currency fluctuations due to its global operations.
Catalizadores
- Ongoing: Expansion of the Advanced Technologies division with new product launches in micro pumps and smart drug delivery systems.
- Ongoing: Increasing demand for injectable drugs driving growth in the Plastics & Devices division.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Upcoming: Potential regulatory approvals for new drug delivery devices in key markets.
- Ongoing: Focus on sustainable packaging solutions attracting environmentally conscious customers.
Riesgos
- Potential: Intense competition from established players and new entrants in the healthcare packaging market.
- Potential: Stringent regulatory requirements and potential product recalls affecting product sales and reputation.
- Potential: Economic downturns affecting healthcare spending and demand for pharmaceutical products.
- Ongoing: Exposure to currency fluctuations due to its global operations.
- Ongoing: Relatively low profit margin compared to industry peers, requiring improved operational efficiency.
Oportunidades de crecimiento
- Expansion of Advanced Technologies Division: Gerresheimer's Advanced Technologies division, which develops smart drug delivery systems like micro pumps, represents a significant growth opportunity. The market for advanced drug delivery systems is projected to reach $24.7 billion by 2027, driven by the increasing demand for personalized medicine and self-administration options. By focusing on innovative solutions for chronic diseases like Parkinson's and heart failure, Gerresheimer can capture a larger share of this expanding market. Timeline: Ongoing.
- Increasing Demand for Injectable Drugs: The rising prevalence of chronic diseases and the growing biologics market are driving increased demand for injectable drugs, creating a significant opportunity for Gerresheimer's Plastics & Devices division. The global injectable drug market is expected to reach $790.7 billion by 2030. Gerresheimer's expertise in manufacturing prefillable syringes and other injectable drug delivery systems positions it well to capitalize on this trend. Timeline: Ongoing.
- Growth in Emerging Markets: Emerging markets, with their rapidly growing populations and increasing healthcare expenditure, present a substantial growth opportunity for Gerresheimer. These markets are experiencing a rising demand for pharmaceutical packaging and drug delivery systems. By expanding its presence in regions like Asia-Pacific and Latin America, Gerresheimer can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Gerresheimer can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. Collaborating with pharmaceutical companies and biotech firms can facilitate the development of innovative drug delivery solutions and secure long-term supply contracts. Acquisitions of complementary businesses can provide access to new markets and technologies. Timeline: Ongoing.
- Focus on Sustainable Packaging Solutions: With increasing environmental awareness, there is a growing demand for sustainable packaging solutions in the healthcare industry. Gerresheimer can capitalize on this trend by developing and offering eco-friendly packaging options, such as recyclable plastics and bio-based materials. By positioning itself as a leader in sustainable packaging, Gerresheimer can attract environmentally conscious customers and gain a competitive advantage. Timeline: Ongoing.
Oportunidades
- Expanding into emerging markets with growing healthcare expenditure.
- Developing innovative drug delivery systems for chronic diseases.
- Acquiring complementary businesses to expand its product portfolio.
- Capitalizing on the increasing demand for sustainable packaging solutions.
Amenazas
- Intense competition from established players and new entrants.
- Stringent regulatory requirements and potential product recalls.
- Economic downturns affecting healthcare spending.
- Disruptive technologies that could render existing products obsolete.
Ventajas competitivas
- Specialized Expertise: Gerresheimer's deep expertise in manufacturing specialized packaging and drug delivery systems creates a barrier to entry for new competitors.
- Long-Term Relationships: The company's long-standing relationships with pharmaceutical companies and biotech firms provide a stable revenue stream and a competitive advantage.
- Regulatory Compliance: Gerresheimer's adherence to stringent regulatory requirements in the healthcare industry ensures product quality and safety, building trust with customers.
- Global Footprint: The company's global manufacturing and distribution network allows it to serve customers in both established and emerging markets.
Acerca de GRRMF
Founded in 1864 and headquartered in Düsseldorf, Germany, Gerresheimer AG has evolved into a leading global manufacturer of packaging products and drug delivery devices. The company operates through three primary divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers a range of drug delivery systems, including inhalers, insulin pen systems, and prefillable syringes, along with diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries. This division also provides containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications, as well as bottles and containers for nutritional supplements. The Primary Packaging Glass division focuses on glass primary packaging for the pharma and cosmetics industries, producing infusion, dropper, and syrup bottles, injection vials, ampoules, and cartridges. Additionally, it offers miniature bottles and glass containers for liquid food, spices, and spirits, along with packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division is dedicated to developing smart drug delivery systems, such as micro pumps, which are used to self-administer medication for conditions like Parkinson's disease or heart failure. Gerresheimer serves a diverse customer base across the pharmaceutical, biotech, diagnostics, medical technology, and cosmetics industries, with a global footprint that allows it to cater to both established and emerging markets.
Qué hacen
- Manufactures plastic containers and closures for liquid and solid pharmaceuticals.
- Produces glass vials, ampoules, and cartridges for injectable drugs.
- Develops and manufactures drug delivery systems, including inhalers and pen systems.
- Offers packaging solutions for the cosmetics and personal care industries.
- Creates advanced micro pumps for self-administration of medication.
- Provides diagnostic systems for the pharma and biotech sectors.
Modelo de Negocio
- Manufacturing and selling primary packaging glass for pharmaceutical and cosmetic products.
- Producing plastic containers and drug delivery systems for the healthcare industry.
- Developing and commercializing advanced drug delivery technologies.
- Generating revenue through long-term supply contracts with pharmaceutical companies.
Contexto de la Industria
Gerresheimer AG operates in the medical instruments and supplies industry, which is characterized by continuous innovation and stringent regulatory requirements. The market is driven by increasing healthcare expenditure, an aging population, and the rising prevalence of chronic diseases. The competitive landscape includes companies like BOEUF, EBOSY, EKTAF, EKTAY, and GENSF, each vying for market share through product differentiation and strategic partnerships. Trends such as personalized medicine and the growing demand for self-administered drug delivery systems are shaping the industry's future.
Clientes Clave
- Pharmaceutical companies requiring primary packaging for drugs.
- Biotech firms needing drug delivery systems for injectable medications.
- Cosmetics companies seeking packaging solutions for beauty products.
- Healthcare providers using diagnostic systems and drug delivery devices.
Finanzas
Gráfico e información
Precio de la acción de Gerresheimer AG (GRRMF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para GRRMF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GRRMF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GRRMF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GRRMF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Uwe Ferdinand Röehrhoff
CEO
Uwe Ferdinand Röehrhoff has served as the CEO of Gerresheimer AG, managing a workforce of 13,632 employees. His background includes extensive experience in the pharmaceutical and healthcare industries. He has held various leadership positions in multinational corporations, focusing on strategic planning, operational excellence, and business development. Röehrhoff's expertise spans across multiple functional areas, including manufacturing, supply chain management, and sales and marketing. His academic credentials include advanced degrees in engineering and business administration.
Historial: Under Uwe Ferdinand Röehrhoff's leadership, Gerresheimer AG has focused on expanding its global footprint and strengthening its position as a leading provider of packaging solutions and drug delivery systems. Key achievements include the successful integration of strategic acquisitions, the implementation of operational efficiency initiatives, and the development of innovative products for the healthcare industry. The company has also made significant investments in research and development to drive future growth.
Información del mercado OTC de GRRMF
The OTC Other tier, where Gerresheimer AG (GRRMF) trades, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited reporting requirements and may not meet the minimum financial standards required for exchange listing. This tier typically includes companies with limited operating history, penny stocks, and those facing financial distress. Investing in OTC Other stocks carries significantly higher risks compared to exchange-listed securities due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Disclosure: The lack of comprehensive and readily available financial information increases the risk of investing in GRRMF.
- Low Liquidity: Limited trading volume can make it difficult to buy or sell shares without affecting the price.
- Price Volatility: OTC stocks are often subject to greater price swings due to lower trading volumes and potential for manipulation.
- Regulatory Scrutiny: OTC-listed companies may face increased regulatory scrutiny and potential delisting.
- Information Asymmetry: The limited availability of information can create an uneven playing field for investors.
- Verify the company's financial statements through independent sources.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Evaluate the company's corporate governance practices.
- Monitor news and regulatory filings related to the company.
- Consult with a financial advisor before making any investment decisions.
- Established Operations: Gerresheimer AG has a long operating history dating back to 1864, suggesting a degree of stability and experience.
- Global Presence: The company's global manufacturing and distribution network indicates a significant scale of operations.
- Industry Recognition: Gerresheimer AG is a recognized player in the healthcare packaging and drug delivery systems market.
- Customer Base: The company serves major pharmaceutical companies and biotech firms, indicating a level of trust and credibility.
- Management Team: The presence of an experienced CEO, Uwe Ferdinand Röehrhoff, suggests capable leadership.
GRRMF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar GRRMF?
Gerresheimer AG (GRRMF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Global presence and established reputation in the healthcare industry.. Riesgo principal a monitorear: Potential: Intense competition from established players and new entrants in the healthcare packaging market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GRRMF?
GRRMF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GRRMF?
Los precios de GRRMF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GRRMF?
La cobertura de analistas para GRRMF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GRRMF?
Las categorías de riesgo para GRRMF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from established players and new entrants in the healthcare packaging market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GRRMF?
La relación P/E para GRRMF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GRRMF sobrevalorada o infravalorada?
Determinar si Gerresheimer AG (GRRMF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GRRMF?
Gerresheimer AG (GRRMF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data may be delayed or incomplete due to OTC listing.
- AI analysis pending for GRRMF.